Diabetes Prevention Program (DPP)

Summary

The Diabetes Prevention Program is one of the most consequential public-health RCTs of the past 30 years and is widely considered the gold-standard example of an intensive lifestyle intervention producing durable health benefits. The 58% reduction in diabetes incidence was so large that the trial was stopped early on ethical grounds — the data and safety monitoring board determined it would be unethical to continue assigning at-risk participants to the placebo arm. What makes the DPP particularly important from a civic-experimentation perspective is the translational arc: the original efficacy trial established what was possible under research conditions, but the National DPP rollout has been an ongoing real-world replication test. Effect sizes in community settings have been smaller (typically 5% rather than 7% weight loss) but still meaningful, and the program's cost-effectiveness in real-world implementation is well-established. The CDC's National DPP has now reached over 600,000 participants — a scale-up that has itself become a case study in evidence-based public-health policy implementation.

Research question

"Among adults at high risk of type 2 diabetes, can an intensive lifestyle intervention (diet, exercise, behavioral coaching) prevent or delay onset of diabetes, and how does it compare to pharmacological prevention with metformin?"

Methodology

Result

Positive

Lifestyle intervention reduced diabetes incidence by 58% vs. placebo; metformin reduced incidence by 31%. The lifestyle effect was largest in older adults (71% reduction in those aged 60+); metformin effect was largest in younger, heavier participants. Long-term follow-up at 15+ years found lifestyle intervention reduced cumulative diabetes incidence by 27% and reduced cardiovascular events.

Evidence strength

Strong

Randomized trial, replicated across multiple sites or studies.

Replication status

Replicated